Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.

Authors:
Ajlan A; Al-Jedai A; Elsiesy H; Alkortas D; Al-Hamoudi W and 4 more

Journal:
Can J Gastroenterol Hepatol

Publication Year: 2016

DOI:
10.1155/2016/2872371

PMCID:
PMC4904700

PMID:
27446833

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Can J Gastroenterol Hepatol

Abbreviation: Can J Gastroenterol Hepatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matche…
Erman A; Sahakyan Y; Everett K and 6 more (2024) - Transparency Score: 3/6
Prevalence of Esophageal Eosinophilia, Eosinophilic Esophagitis, and Lymphocytic Gastritis in Child…
Alaifan MA; Khayat A; Bokhary RY and 4 more (2024) - Transparency Score: 2/6
Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest.
Wang Y; Ma L; Xue P and 6 more (2023) - Transparency Score: 3/6
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patient…
Di Cola S; Cusi G; Lapenna L and 6 more (2023) - Transparency Score: 2/6
Disparate Intent-to-Treat Outcomes for Pediatric Liver Transplantation Based on Indication.
Lang A; Goff C; Montgomery A and 4 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing Interests The authors of this paper have no competing interests to disclose."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025